HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Crosssectional Design

Nanfack, Aubin; Takou, Désiré; Fokam, Joseph; Salpini, Romina; Santoro, Maria Mercedes; Cappelli, Giulia; Baane, Martin Paul; Tetang, Suzie Moyo; Eberle, Josef; Gürtler, Lutz; Ceccherini‐Silberstein, Francesca; Torimiro, Judith; Colizzi, Vittorio; Perno, Carlo Federico; Ndjolo, Alexis

doi:10.2174/1570162x14666161230105417

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The described demographics feat with the local HIV epidemics, thus supporting the representativeness of our findings to the target population ( 14 , 43 – 46 ). In effect, from a total of more than 12.000 patients monitored in our routine clinical practice, we carefully screened for participants fully complying with all study criteria.…”

Section: Discussionsupporting

confidence: 83%

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

et al. 2022

Self Cite

View full text Add to dashboard Cite

We described the analysis of the genotypes of the population within third-line antiviral therapy in Cameroon, with a focus on defining the effects of prior raltegravir (RAL) treatment and resistance mutations for current dolutegravir (DTG) treatment. While supporting the current transition to DTG-containing ART in resource-limited settings toward the achievement of the UNAIDS’ goal of HIV elimination by 2030, our findings suggested that RAL-exposed patients may need a specific monitoring approach either in a stratified or personalized model of third-line ART to ensure the long-term success of DTG-containing regimens.

show abstract

Section: Discussionsupporting

confidence: 83%

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…For the sequences obtained from our laboratory, HIV-1 integrase genotyping was performed as previously described by Nanfack et al 44 Briefly, after viral RNA extraction from plasma samples, RNA was reversetranscribed and amplified. From positive amplicons, DNA sequencing was performed using four overlapping sense and antisense sequencespecific primers.…”

Section: Amplification and Sequencing Of Hiv-1 Integrase Regionmentioning

confidence: 99%

Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings

Semengue

Armenia

Inzaule

et al. 2021

Journal of Antimicrobial Chemotherapy

Self Cite

View full text Add to dashboard Cite

Background Transition to dolutegravir-based regimens in resource-limited settings (RLS) requires prior understanding of HIV-1 integrase variants and conserved regions. Therefore, we evaluated integrase drug resistance mutations (DRMs) and conserved regions amongst integrase strand transfer inhibitor (INSTI)-naive patients harbouring diverse HIV-1 clades in Cameroon. Methods A cross-sectional study was conducted amongst 918 INSTI-naive patients from Cameroon (89 ART-naive and 829 ART-experienced patients). HIV-1 sequences were interpreted regarding INSTI-DRMs using the Stanford HIVdb v8.9-1 and the 2019 IAS–USA list. Amino acid positions with <1% variability were considered as highly conserved. Subtyping was performed by phylogeny. Results Overall prevalence (95% CI) of INSTI-DRMs was 0.8% (0.4–1.7), with 0.0% (0.0–4.0) amongst ART-naive versus 0.9% (0.5–1.9) amongst ART-experienced patients; P = 0.44. Accessory mutations (95% CI) were found in 33.8% (30.9–37.0), with 38.2% (28.1–49.1) amongst ART-naive versus 33.4% (30.4–36.7) amongst ART-experienced patients; P = 0.21. Of 288 HIV-1 integrase amino acid positions, 58.3% were highly conserved across subtypes in the following major regions: V75–G82, E85–P90, H114–G118, K127–W132, E138–G149, Q168–L172, T174–V180, W235–A239 and L241–D253. Wide genetic diversity was found (37 clades), including groups M (92.3%), N (1.4%), O (6.2%) and P (0.1%). Amongst group M, CRF02_AG was predominant (47.4%), with a significantly higher frequency (95% CI) of accessory mutations compared with non-AG [41.4% (36.8–46.0) versus 27.1% (23.3–31.2) respectively; P < 0.001]. Conclusions The low baseline of INSTI-DRMs (<1%) in Cameroon suggests effectiveness of dolutegravir-based regimens. In spite of high conservation across clades, the variability of accessory mutations between major circulating strains underscores the need for monitoring the selection of INSTI-DRMs while scaling up dolutegravir-based regimens in RLS.

show abstract

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection—authors’ response

Nozza

Poli

Ripa

et al. 2017

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Crosssectional Design

Cited by 4 publications

References 0 publications

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings

Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection—authors’ response

Contact Info

Product

Resources

About